A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Surgical mask partition reduces the risk of non-contact transmission in a golden Syrian hamster model for Coronavirus Disease 2019 (COVID-19)

(2020) Jasper Fuk-Woo Chan et al.   CLINICAL INFECTIOUS DISEASES

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

(2020) Till Koch et al.   LANCET INFECTIOUS DISEASES

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) Fatima Amanat et al.   NATURE MEDICINE

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection

(2020) Kun Li et al.   mBio

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

(2020) Masaki Imai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine

(2020) Claire Smalley Rumfield et al.   Journal for ImmunoTherapy of Cancer

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

(2020) Kenneth H. Dinnon et al.   NATURE

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

(2020) Weina Sun et al.   EBioMedicine

Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response

(2019) Siva K. Gandhapudi et al.   JOURNAL OF IMMUNOLOGY

Combining R -DOTAP and a particulate antigen delivery platform to trigger dendritic cell activation: Formulation development and in-vitro interaction studies

(2017) Markus Riehl et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial

(2017) Anuradha Madan et al.   VACCINE

Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels

(2017) Ren-qiang LIU et al.   Journal of Integrative Agriculture

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial

(2015) Long Wang et al.   Journal of the Pediatric Infectious Diseases Society

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial

(2014) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Trp2 Peptide Vaccine Adjuvanted with (R)-DOTAP Inhibits Tumor Growth in an Advanced Melanoma Model

(2011) Elizabeth A. Vasievich et al.   MOLECULAR PHARMACEUTICS

Production of Newcastle Disease Virus by Vero Cells Grown on Cytodex 1 Microcarriers in a 2-Litre Stirred Tank Bioreactor

(2010) Mohd Azmir Arifin et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

(2008) Matthias Liniger et al.   VACCINE